Raffles Medical Group Ltd – 1H 2026 Financial Analysis

Raffles Medical Group Ltd (“RMG”) has released its unaudited condensed interim financial statements for the six months ended 30 June 2026. The following analysis summarizes the company’s key financial metrics, performance drivers, and outlook, focusing on details disclosed in the official report.

Key Financial Metrics

* Breakdown for 2H 2025 is not available in the interim report.
** No interim dividend declared for 1H 2026; 3.0 cents is the final dividend paid in April 2026 for FY2025.

Performance Highlights & Trends

• Revenue: Fell 6.7% YoY to S\$353.2 million, mainly due to lower occupancy in transitional care facilities (Healthcare Services segment) and reduced insurance revenue, partly offset by continued China operations growth.
• Net Profit: Down 9.6% YoY to S\$29.0 million. The decline reflects lower revenue, partially cushioned by cost optimization and efficiency gains in the Hospital Services segment.
• Segmental Analysis:
  • Hospital Services: Revenue S\$170.2 million (stable), with profit up 11% YoY to S\$19.7 million, driven by improved efficiency and cost management in both Singapore and China. Division profit margin rose from 10.2% to 11.6%.
  • Healthcare Services: Revenue S\$119.5 million, down 16% YoY, as a result of lower transitional care occupancy. Segment profit dropped to S\$15.6 million from S\$24.9 million.
  • China Operations: Revenue grew 13% YoY in CNY terms, reflecting increased brand recognition and cost optimization.
  • Insurance Services (RHI): Revenue fell to S\$88.5 million (from S\$94.9 million), but operating loss narrowed sharply to S\$1.1 million (from S\$3.1 million) on improved claims experience and cost control.
• Cash Flow & Dividends: Operating cash flow rose to S\$64.6 million (up from S\$56.6 million). In 1H 2026, the Group paid a S\$55.2 million final dividend and fully repaid S\$51.1 million of bank loans. No interim dividend was declared for the period.
• Balance Sheet: Cash and equivalents stood at S\$262.3 million, down from S\$310.8 million at FY2025-end, due to dividend payouts and debt repayment.

Exceptional Items & Notable Events

• Foreign Exchange: The Group reported a S\$1.6 million forex gain in 1H 2026, versus a S\$1.7 million loss in 1H 2025.
• Share Buybacks: No new buybacks in 1H 2026, but 44.4 million treasury shares (2.41% of issued shares) are held.
• Loans: All outstanding bank loans were fully repaid during the period; Group now has zero bank debt.
• Asset Valuation: No revaluation of investment properties during 1H 2026; management asserts no significant changes in valuation factors since December 2025.
• Dividends: Final dividend for FY2025 was raised to 3.0 cents per share (from 2.5 cents in the previous year). No interim dividend for 1H 2026, in line with the Group’s annual dividend policy.
• Directors’ Pay: Not disclosed in the interim report.

Chairman’s Statement

“The Group remains focused on delivering integrated healthcare and insurance solutions that address the evolving needs of individuals and corporate clients. By leveraging its comprehensive healthcare ecosystem, the Group is well positioned to provide accessible, coordinated and high-quality care while generating sustainable long-term value for its stakeholders.

Innovation and digital transformation remain key strategic priorities. The Group will continue to evaluate and adopt appropriate technologies, including artificial intelligence (AI), to improve operational efficiency, enhance service excellence and support the delivery of safe, high-quality healthcare services.

As the Group marks its 50th Anniversary in 2026, it remain guided by its core values of Compassion, Commitment, Excellence, Teamwork and Value (CCETV). Building on five decades of service to the communities in which it operates, the Group will continue to innovate, strengthen its capabilities and enhance patient care in support of its mission to deliver trusted healthcare.

While the operating environment remains challenging, the Directors are optimistic that, barring unforeseen circumstances, the Group will remain profitable for the financial year ending 31 December 2026.”

Tone: The Chairman’s statement is cautiously optimistic, highlighting resilience, innovation, and profitability despite external macroeconomic uncertainties and an evolving competitive environment.

Outlook

• Macroeconomic risks remain due to global uncertainty, geopolitical tension, and volatile financial markets, but healthcare demand is expected to be resilient.
• The Group is focusing on regional expansion, digital transformation, and leveraging its integrated healthcare-insurance ecosystem.
• No interim dividend was declared, in line with the Group’s move to annual core dividends.

Conclusion & Investment Recommendation

Overall Assessment: The Group’s 1H 2026 performance is somewhat weaker than the previous year in terms of revenue and profit, mainly due to Healthcare Services weakness and insurance revenue declines. However, the business remains profitable, cash-generative, and debt-free, with improved margins in Hospital Services and a solid financial position.

• If you are currently holding RMG stock: Consider maintaining your position. The Group remains fundamentally sound, cash-generative, and is executing well in its core hospital business and China expansion. The lack of interim dividend aligns with the annual payout policy, and the business outlook remains cautiously positive.
• If you are not currently holding RMG stock: Wait for a clearer upturn in Healthcare Services or for signs of sustained revenue/profit growth. The stock could be attractive for long-term investors given its strong balance sheet and leadership in integrated healthcare, but near-term earnings momentum is muted.

Disclaimer: This analysis is based solely on the company’s disclosed interim financial statements and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consider their individual risk tolerance.

莱佛士医疗集团2026年上半年财报分析

莱佛士医疗集团有限公司（RMG）公布了截至2026年6月30日的中期财务报表。以下分析根据公司官方报告，梳理了关键财务指标、业绩驱动因素与未来展望。

主要财务指标

* 报告未披露2025年下半年单独数据。
** 2026年上半年未派发中期股息，3.0分为2025财年4月支付的末期股息。

业绩亮点与趋势

• 营收：同比下降6.7%，主要受医疗服务板块过渡护理床位入住率下降及保险业务收入减少影响，中国业务持续增长部分缓解下滑。
• 净利润：同比下滑9.6%，收入减少被医院服务效率提升和成本优化部分抵消。
• 分部表现：
  • 医院服务：营收持稳，利润同比增长11%，利润率由10.2%升至11.6%，得益于新加坡和中国医院的运营效率提升。
  • 医疗服务：营收同比下降16%，利润由2,490万新元跌至1,560万新元，主要因过渡护理床位需求下滑。
  • 中国业务：以人民币计收入同比增长13%，品牌影响力提升与成本优化见效。
  • 保险服务：营收降至8,850万新元，但运营亏损缩小至110万新元，主要因理赔改善与成本管控。
• 现金流与分红：经营性现金流增至6,460万新元。上半年支付5,520万新元末期股息，并全额偿还5,110万新元银行贷款。未派发中期股息。
• 资产负债表：期末现金及等价物为2.62亿新元，较去年底大幅下降，主要因分红和还债。

特殊事项及公司动态

• 汇兑：2026年上半年录得汇兑收益161.5万新元，而去年同期为亏损173.2万新元。
• 股票回购：本期无新增回购，持有4,435万库存股，占发行股本2.41%。
• 贷款：已全部偿还银行贷款，集团无银行债务。
• 资产估值：上半年未重新估值投资性房地产，管理层认为自2025年12月以来无重大变动因素。
• 分红：2025财年末期股息提升至每股3.0分（前一年为2.5分），2026年上半年未派发中期股息，符合公司年度分红政策。
• 董事薪酬：本报告未披露。

董事长寄语

“集团将继续专注于提供一体化医疗与保险解决方案，满足个人及企业客户不断变化的需求。凭借全面的医疗生态系统，集团能够提供可获得、协调且高质量的护理，同时为利益相关者创造可持续的长期价值。

创新与数字化转型仍是集团的战略重点，将持续评估并采纳包括人工智能（AI）在内的适当技术，提升运营效率和服务体验，支持安全高质量医疗服务的交付。

2026年集团将迎来50周年纪念，始终秉持‘关怀、承诺、卓越、团队合作、价值’的核心价值观。在五十年服务社区的基础上，集团将继续创新，强化能力，提升病患护理，践行‘值得信赖的医疗’使命。

尽管经营环境依然充满挑战，董事会仍对集团在2026财年实现盈利保持乐观（如无不可预见情况）。”

点评：董事长对公司前景表示谨慎乐观，强调韧性、创新与盈利能力，正视外部宏观不确定性与激烈竞争。

未来展望

• 全球宏观经济风险持续，地缘政治紧张及金融市场波动，但医疗需求预计将保持韧性。
• 集团持续拓展区域网络，推动数字化转型，发挥医疗-保险一体化优势。
• 未派发中期股息，符合年度分红政策。

结论与投资建议

总体评价：集团2026年上半年业绩较去年同期略显疲软，主要因医疗服务板块下滑和保险业务收入减少。不过，集团依然保持盈利、现金流强劲且无银行债务，医院服务与中国业务表现稳健，财务状况良好。

• 若已持有RMG股票：建议继续持有。公司基本面稳健，现金流充裕，医院主业和中国扩张推进顺利。未派发中期股息符合年度分红政策，未来展望保持谨慎乐观。
• 若未持有RMG股票：建议观望，等待医疗服务板块需求回升或公司营收/利润增长信号更明确后再考虑介入。公司具备长期投资吸引力，但短期盈利动力偏弱。

免责声明：本分析仅基于公司中期财报公开内容，不构成买卖建议或投资意见。投资者应结合自身风险承受能力，独立进行充分调研后决策。

View Raffles Medical Historical chart here